摘要
目的:探讨氨氯地平及氨氯地平联合特拉唑嗪改善男性下尿路症状(LUTS)合并高血压患者残余尿(PVR)的疗效。方法:360例男性BPH合并高血压患者进入随机双盲临床实验,随机进入特拉唑嗪(2 mg/d)、氨氯地平(5 mg/d)、联合用药组(特拉唑嗪2 mg/d+氨氯地平5 mg/d)3个治疗组,各120例,分别测定治疗4周前后的PVR值。应用非参检验及回归分析氨氯地平及联合用药的有效性。结果:对于男性LUTS合并高血压患者,氨氯地平(ΔPVR=6.8)、特拉唑嗪(ΔPVR=7.6)及联合用药(ΔPVR=8.8)均能能有效降低PVR(P均<0.01),但三者间疗效无明显差异。结论:氨氯地平单独或联合特拉唑嗪可以有效改善LUTS患者PVR,但效果与单用特拉唑嗪并无明显区别。
Objective：This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual （PVR） in patients with lower urinary tract symptoms （LUTS） and concomitant hypertension. Methods： We randomly divided 360 LUTS patients with concomitant hypertension into a 5 mg amlodipine group, a 2 mg terazosin group and a 5 mg amlodipine plus 2 mg terazosin group, and measured PVR at the baseline and 4 weeks after the treatment. Results ： For male patients with LUTS associate with hypertension, all of amlodipine （ APVR = 6.8 ） , terazosin （ APVR = 7.6）, and combination group （ APVR = 8.8 ） can significant reduced the PVR （ P 〈 0. 01 ）, but no significant difference was found among three groups. Conclusion ： Amlodipine alone or combined with terazosin can improve the PVR of the LUTS patient effectively, but had no significant difference compared with terazosin.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2009年第5期441-444,共4页
National Journal of Andrology
关键词
残余尿
良性前列腺增生
高血压
氨氯地平
特拉唑嗪
postvoid residual
benign prostatic hyperplasia
hypertension
amlodipine
terazosin
